UNICYCIVE THERAPEUTICS, INC. Proceeds from Debt, Net of Issuance Costs
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Proceeds from Debt, Net of Issuance Costs of $28.00 million for the 0-month period ending 2023-03-03, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2023-11-14
- UNICYCIVE THERAPEUTICS, INC. proceeds from debt, net of issuance costs for the quarter ending 2021-09-30 was $2.70M.
| Period end | Proceeds from Debt, Net of Issuance Costs 0 month | Proceeds from Debt, Net of Issuance Costs 3 month |
|---|---|---|
| 2023-03-03 | $28.00M 10-Q · filed 2023-11-14 | |
| 2021-09-30 | $2.70M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |